中国临床药理学杂志2017，Vol.33Issue(23)：2375-2377,3.DOI:10.13699/j.cnki.1001-6821.2017.23.014
米非司酮治疗子宫内膜异位症的临床研究
Clinical trial of mifepristone in the treatment of patients with endometriosis
摘要
Abstract
Objective To observe the clinical efficacy of endometriosis mifepristone and its effects on B cell lymphoma-2/B cell lymphoma-2associated X protein (Bcl-2/Bax),suppressor of cytokine signaling-3 (SOCS-3) and caspase-3.Methods One hundred and forty patients with endometriosis were divided into treatment group and control group,70 cases in each group.Treatment group was treated with mifepristone 10 mg orally,qd.Control group was treated with tamoxifen 10 mg each time orally,bid.All patients were treated for six months.The clinical efficacy and the levels of SOCS-3,Bcl-2/Bax,caspase-3 were observed in two groups before and after treatment.Results After treatment,the clinical efficacy in treatment group and control group were 85.71％ (60 cases/70 cases),81.43％ (57 cases/70 cases),without significant difference (P ＞0.05).After treatment,SOCS-3,Bcl-2/Bax and caspase-3 in treatment group were 7.62 ± 1.31,0.82 ± 0.22,5.52 ± 1.22,had significant difference with those in control group,which were 6.32 ±l.48,1.61 ±0.13,3.21 ± 1.87 (P ＜0.05).During the treatment,there were 1 case of nausea and 1 case of headache in treatment group,with the incidence of 2.86％ (2 cases/70 cases).There were 5 cases of vomiting,3 cases of shortness breath,1 case of vulvar itching in control group,with the incidence of 12.86％ (9 cases/70 cases).There was significant difference in the incidence of adverse drug reactions between the two groups (P ＜ 0.05).Conclusion The clinical efficacy of mifepristone in the treatment of endometriosis patients is great,mainly through the regulation of SOCS-3,Bcl-2/Bax,caspase-3 expression.关键词
子宫内膜异位症/米非司酮/细胞因子信号传导抑制蛋白-3/B淋巴细胞瘤-2基因/B淋巴细胞瘤-2基因相关X蛋白/胱天蛋白酶-3Key words
endometriosis/mifepristone/suppressor of cytokine signaling-3/B cell lymphoma-2/B cell lymphoma-2 associated X protein/caspase-3分类
医药卫生引用本文复制引用
付楝,郑若姮..米非司酮治疗子宫内膜异位症的临床研究[J].中国临床药理学杂志,2017,33(23):2375-2377,3.基金项目
浙江省医药卫生科技计划基金资助项目(2012KYA159) （2012KYA159）
